Compare MG & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MG | NVCT |
|---|---|---|
| Founded | 1978 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 642.4M | 672.1M |
| IPO Year | 2008 | 2021 |
| Metric | MG | NVCT |
|---|---|---|
| Price | $20.21 | $20.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | $21.18 | ★ $35.40 |
| AVG Volume (30 Days) | ★ 347.1K | 185.6K |
| Earning Date | 11-27-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $700,970,000.00 | N/A |
| Revenue This Year | $3.15 | N/A |
| Revenue Next Year | $5.40 | N/A |
| P/E Ratio | $39.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.13 | $5.77 |
| 52 Week High | $21.92 | $29.28 |
| Indicator | MG | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 49.38 |
| Support Level | $20.06 | $19.78 |
| Resistance Level | $21.77 | $22.49 |
| Average True Range (ATR) | 0.11 | 1.41 |
| MACD | -0.04 | 0.19 |
| Stochastic Oscillator | 30.61 | 54.14 |
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International, and Products and Systems, of which key revenue is derived from the North America segment. The North America segment provides asset protection solutions, including NDT, inspection, and mechanical and engineering services, along with software, digital, and data services.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.